Drug Profile
TNFR2-Fc-IL-1ra
Alternative Names: TFI - Hangzhou Anruipu Biological TechnologyLatest Information Update: 14 Apr 2016
Price :
$50
*
At a glance
- Originator Hangzhou Anruipu Biological Technology
- Class Interleukins; Recombinant fusion proteins; Tumour necrosis factors
- Mechanism of Action Interleukin 1 receptor antagonists; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 14 Apr 2016 No recent reports on development identified - Preclinical for Inflammation in China (unspecified route)